Biogal-Galed Labs Launches CombCam, an Automated Reading Device for Biogal’s VacciCheck and ImmunoComb Kits

KIBBUTZ GALED, Israel, Sept. 18, 2019 /PRNewswire/ — Biogal Galed Labs, a global leader of veterinary diagnostic solutions, has announced the commercialization of the new CombCam, an automated reading device for Biogal’s VacciCheck and ImmunoComb kits.

This will make the interpretation of VacciCheck and ImmunoComb easier, less cumbersome, faster, digitalized and more accurate, says Amos Gershony, Biogal’s CEO.

This user friendly, add on technology, will greatly assist veterinarians in the vet clinic/ vet lab setting.

CombCam now offers the following benefits:

  • A Hand sized, user friendly reader. 
  • Reads individually one tooth at a time.
  • Result displayed after 3 seconds.
  • Test results can be copied to a PC or a laptop for electronic documentation.
  • “Electronic Eye” reads ImmunoComb/ VacciCheck semi quantitatively.

The CombCam is available for all of Biogal’s for Canine and Feline VacciCheck/ImmunoComb kits.

CLICK HERE for the official CombCam How to Use Video.

About Biogal-Galed Labs:

Biogal was established in 1986. Biogal’s various veterinary diagnostic products are available in over 35 countries.

Biogal developed the patented ImmunoComb, VacciCheck and PCRun technologies for the detection of pet infectious diseases.

Please visit www.biogal.com for more information.

For more information, contact:

Lenny Small
VP Marketing
Biogal, Galed Labs Acs Ltd.
Kibbutz Galed, 1924000, Israel
Phone: +972(0)4-9898605
len@biogal.co.il

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/biogal-galed-labs-launches-combcam-an-automated-reading-device-for-biogals-vaccicheck-and-immunocomb-kits-300920779.html

SOURCE Biogal Galed Labs

Staff

Recent Posts

Vaxxas Secures TGA Licence to Manufacture Therapeutic Goods

Milestone enables GMP manufacturing to accelerate clinical trials and transform global vaccine delivery BRISBANE, Australia…

31 minutes ago

InnoCare Announces Achievement of Primary Endpoint in Phase IIb Study of Orelabrutinib for SLE and Approval of Phase III Clinical Trial

BEIJING, Dec. 14, 2025 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading…

31 minutes ago

President Trump’s Cannabis Decision Is Coming – And Why MMJ International Holdings Wins Either Way

12 Month Timeline - How Cannabis Rescheduling Actually Takes EffectAnnouncementPresident signals intent or issues executive…

19 hours ago

Accelerating Patient Recruitment and Research Excellence: TrialWire® Supports Endpoints Clinical Trials Day NYC 2025

NEW YORK, Dec. 12, 2025 (GLOBE NEWSWIRE) -- TrialWire®, the industry’s fastest, intelligent patient recruitment…

1 day ago

Genesis Healthcare Remains Committed to Securing Longterm Stability

The skilled nursing, assisted and senior living provider reiterates dedication to a financial restructuring process…

1 day ago